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ABSTRACT  
Objectives 
Breathlessness is common in patients with advanced cancer and almost universal in advanced 
chronic obstructive pulmonary disease (COPD), but studies suggest their experiences of 
breathlessness vary. This report builds on these studies by providing quantitative evidence of 
differences in respiratory health-related quality of life (HRQoL) between these groups. 
Further, it explores the validity of the Chronic Respiratory Questionnaire (CRQ) in patients 
with cancer. 
Methods  
The CRQ-Original was completed within baseline interviews for a randomised controlled trial 
of a palliative intervention for intractable breathlessness due to advanced disease. 
Independent-Samples Mann-Whitney U Tests were performed to identify significant 
differences in median scores for the four CRQ domains (mastery, dyspnoea, emotional 
function, fatigue) in patients with advanced COPD (n=73) or advanced cancer (n=67.) The 
Minimally Clinically Important Difference (MCID) of 0.5 was applied to determine clinical 
significance. 
Results  
Patients with advanced COPD scored lower across all four CRQ domains. This was 
statistically significant for dyspnoea, mastery, and emotional function (p<0.05), and clinically 
significant for the latter two, suggesting poorer respiratory HRQoL. 
Conclusions  
Patients with breathlessness due to advanced COPD have worse respiratory HRQoL than 
those with advanced cancer. This may result from greater burden of breathlessness in COPD 
due to condition-longevity, lesser burden of breathlessness in cancer due to its episodic 
nature, or variance in palliative referral thresholds by disease group. Our results suggest 
greater access to palliative care is needed in advanced COPD and that formal psychometric 
testing of the CRQ may be warranted in cancer. 
 
BACKGROUND 
Breathlessness, the most common symptom of advanced chronic obstructive pulmonary 
disease (COPD), is also highly prevalent in cancers of all primary sites.[1] A recent study 
demonstrated that patients with COPD differ significantly in their experiences of 
breathlessness compared to patients with cancer, and that such differences are important for 
effective intervention targeting.[2] Little is known about the impact of these differences on 
respiratory health-related quality of life (HRQoL.) Greater understanding of this could help 
determine effective ways to palliate symptoms in these diagnostic groups. Further, there is 
significant demand in the literature for a single HRQoL outcome measure suitable for use 
across disease groups to enable comparison within and between studies and disciplines.[3,4] 
For example, Parshall et al. have commented that studies of breathlessness are too often 
‘siloed by disease or by specialty or by disciplinary focus.’[4] Exploration of HRQoL data 
collection using a single outcome measure across disease groups is therefore warranted. 
 
The Chronic Respiratory Questionnaire-Original (CRQ-Original) is an interviewer-
administered respiratory HRQoL questionnaire that is reproducible, responsive, and widely 
used for research. Other versions, such as the CRQ-SA (self-administered), have been 
developed, and are reportedly as valid as the original.[5] The CRQ’s relative brevity increases 
its potential for use within clinical practice. It produces scores of 0-7 (lower score represents 
poorer respiratory HRQoL) across four respiratory HRQoL domains: dyspnoea (how 
breathless the patient feels), mastery (how in control of their condition the patient feels), 
emotional function (extent to which their condition affects them emotionally), and fatigue 
(extent to which their condition makes them feel tired.) The CRQ is validated for use in 
chronic airflow limitation and many other conditions but not, as yet, in cancer.[3, 6] 
However, given the commonality of respiratory symptoms in patients with cancer, the CRQ 
has frequently been used as a research tool in this diagnostic group.[7] Indeed, two recent 
  
randomised controlled trials (RCT) of breathlessness interventions used the CRQ as an 
outcome measure in patients with breathlessness to due advanced cancer.[7,8] In the 
Cambridge study[8] the tool was well received by patients with cancer; they did not question 
the relevance of items, or appear challenged in responding to them, suggesting face 
validity.[Personal Communication. Farquhar MC. 20/04/2015] There is also increasing 
evidence that cancer should be seen as a chronic disease,
 
potentially increasing the relevance 
of outcome measures for chronic illness to this diagnostic group.[4] Nonetheless, no 
consensus has been reached on whether the CRQ is valid for measuring respiratory HRQoL in 
cancer. The validation of the CRQ for use in this diagnostic group would provide a single 
outcome measure for analysis of respiratory HRQoL in both malignant and non-malignant 
disease, for which there is demand.  
 
AIM 
This report aims to provide quantitative evidence of differences in respiratory HRQoL 
between patients with breathlessness due to advanced COPD or advanced cancer. This builds 
on previous research highlighting that these diagnostic groups experience breathlessness 
differently, and responds to the demand in the literature for further exploration of how these 
two groups compare in their experiences of breathlessness.[1] Secondly, it aims to explore 
whether formal psychometric testing of the CRQ to establish its use as a respiratory HRQoL 
instrument for patients with cancer is warranted. 
 
METHODS 
Data were collected within baseline interviews for a Phase III single-blinded fast-track 
pragmatic RCT of the Cambridge-based multidisciplinary palliative care service CBIS: a 
complex intervention delivering pharmacological and non-pharmacological interventions to 
patients with intractable breathlessness of any cause, including advanced COPD or advanced 
cancer of any primary site.[8] Independent-Samples Mann-Whitney U Tests were used to 
determine whether there were statistically significant differences between the median 
mastery, dyspnoea, fatigue, and emotional function CRQ scores of patients with COPD 
(n=73) or cancer (n=66; 49.3% lung, 19.4% breast.) The Minimally Clinically Important 
Difference (MCID) of 0.5 was applied to the differences of means to determine if there was a 
clinically significant difference between the mean CRQ scores of patients with COPD and 
cancer; the mean was used rather than medians as the MCID was originally determined using 
means.[10] An Independent-Samples T-Test and Chi-squared test were used to determine if 
there was any significant difference in age or sex respectively between the two diagnostic 
groups.  
 
RESULTS 
The patients’ median Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
classifications (COPD: 3, IQR=1) and Australian Modified Karnofsky scores (cancer: 70, 
IQR=20; COPD: 60, IQR=30) reflect their advanced disease stage. Patients with advanced 
COPD had a lower median score across all four CRQ domains compared to patients with 
advanced cancer. These differences were statistically significant for the dyspnoea, emotional 
function, and mastery domains (p<0.05.) Differences in the means were clinically significant 
for the mastery and emotional function domains when the MCID threshold of 0.5 was 
applied, but not for the fatigue or dyspnoea domains.[Table 1] There was no significant 
difference in the mean age of patients by diagnostic group (COPD: 71.12 years, SD=10.07; 
cancer: 68.66 years, SD=11.46; t=1.36, p=0.178.) However, there was a significant difference 
in sex by diagnostic group, with a greater proportion of males in the advanced COPD group: 
45 male and 28 female in the COPD group, and 26 male and 40 female in the cancer group 
(x
2
 (1, N=139) =6.867, p=0.009.) Therefore, independent-Samples Mann-Whitney U Tests 
were used to compare median CRQ scores by sex in each diagnostic group. In both diagnostic 
groups, there was no statistical difference in the median CRQ scores by sex for the dyspnoea, 
emotional function, and mastery domains, demonstrating that differences in sex did not have 
a statistically significant effect on the CRQ scores. 
  
Table 1             CRQ-Original scores by diagnostic group with associated p values  
CRQ Domain Advanced 
Diagnostic 
Group 
Median 75
th
-25
th
 
Percentiles 
Mean Standard 
deviation 
P value from 
Independent-
Samples Mann-
Whitney U Test 
Differences in 
Means for 
MCID 
Calculation   
Mastery 
 
COPD 3.75 4.75-2.75 3.81 1.28 0.001* 0.71** 
Cancer 4.50 5.50-1.75 4.52 1.22 
Dyspnoea 
 
COPD 3.00 3.60-2.40 3.02 0.93 0.038* 0.39 
Cancer 3.50 4.00-2.60 3.41 0.98 
Fatigue 
 
COPD 2.88 3.75-2.00 2.97 1.13 0.126 0.32 
Cancer 3.25 4.19-2.25 3.29 1.20 
Emotional 
Function 
COPD 3.86 4.33-3.11 3.84 1.13 0.004* 0.51** 
Cancer 4.50 5.14-3.57 4.35 1.06 
*p<0.05, **meets MCID=0.5 as the threshold for clinically significant difference  
 
DISCUSSION 
Patients with advanced COPD referred for a palliative intervention for breathlessness had 
lower median scores across all four domains of the CRQ compared to patients with 
breathlessness due to advanced cancer. These differences were statistically significant for the 
dyspnoea, mastery, and emotional function domains, and clinically significant for the latter 
two domains. The differences were not explained by differences in sex between the two 
groups. This suggests that patients with advanced COPD referred for specialist palliative 
support had worse respiratory HRQoL than patients with breathlessness due to advanced 
cancer.  
 
There are three possible reasons for this finding. Firstly, patients with COPD experience 
respiratory symptoms such as breathlessness much earlier in their disease trajectory, and for a 
longer period of time, compared to patients with breathlessness due to cancer.[11] This 
longevity could result in a greater burden of the symptom, resulting in a worse respiratory 
HRQoL. Secondly, experience of breathlessness in cancer is more episodic than in 
COPD.[12] Patients with cancer may, therefore, spend less time experiencing breathlessness 
and experience times of respite from the symptom, resulting in a lesser overall breathlessness 
burden, and, therefore, better respiratory HRQoL. Thirdly, it is possible that the threshold for 
referring patients with advanced COPD to specialist palliative support is higher than for those 
with advanced cancer.  
 
These findings have implications for both clinical and research practice. The clinical 
implication relates to access to palliative care in patients with advanced COPD. It has been 
established that access to palliative care is poor for these patients compared to those with 
cancer, despite studies indicating that patients with advanced COPD have an equal or greater 
symptom burden than patients with cancer.[11, 13-15] Our data confirms their poorer 
respiratory HRQoL, suggesting the need for major improvements in access to palliative 
support for these patients. 
 
  
The research implication relates to whether the CRQ-Original should be validated as an 
appropriate tool to assess respiratory HRQoL in patients with cancer. Our data suggest that 
the CRQ-Original is sensitive to detecting differences in respiratory HRQoL between patients 
with advanced COPD and cancer, increasing its potential for use in this diagnostic group. If 
found to be valid, this would provide a single tool that could be used across disease groups, 
which would be advantageous in palliative care research across malignant and non-malignant 
disease. Formal psychometric testing of the CRQ in advanced cancer may therefore be 
warranted. In tandem to this, given the short nature of the CRQ (its self-administered versions 
in particular), its validation across malignant and non-malignant disease could have utility for 
clinical practice.  
 
CONCLUSION 
Acknowledging that patients with advanced COPD experience breathlessness differently from 
those with cancer is imperative if we are to direct our interventions effectively and improve 
access to palliative care for patients with advanced COPD. Further, formal psychometric 
testing of the CRQ in patients with respiratory symptoms due to cancer may be warranted to 
establish its suitability for use in this group, which could benefit both research and clinical 
practice.  
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